Australia · Delayed Price · Currency is AUD ALS Limited Earnings Call Transcripts
Fiscal Year 2026
-
Record FY 2026 results with revenue up 10.7% and NPAT up 25.8%, achieving FY 2027 targets a year early. Strong organic growth in Commodities and Life Sciences, robust cash generation, and disciplined capital allocation support continued investment and margin expansion into FY 2027.
-
Revenue grew 13.3% to AUD 1.7 billion with strong organic and acquisition-driven growth, while underlying EBIT rose 14.7% and NPAT increased 17.2%. Upgraded FY26 organic revenue guidance to 6%-8%, with commodities and life sciences showing robust performance but some regional and segment-specific headwinds.
Fiscal Year 2025
-
A refreshed strategy focuses on disciplined capital allocation, digital transformation, and targeted growth in minerals and environmental sectors. AI and automation are driving efficiency and margin gains, while a strong M&A pipeline and sustainability commitments support long-term value creation.
-
FY2025 saw strong revenue growth, robust margins, and significant investment in lab upgrades and digital transformation. The board addressed succession, remuneration, and sustainability, while shareholders engaged on governance, capital raising, and strategic direction. Voting outcomes and future targets were outlined.
-
FY2025 saw 16% revenue growth and resilient EBIT, with strong cash conversion and robust performance in both commodities and life sciences. Major lab upgrades and an AUD 350 million equity raise will support future growth, while margin expansion and 5%-7% organic growth are targeted for FY2026.
-
Underlying EBIT rose 2.1% to AUD 250 million, with revenue up 14% to AUD 1.4 billion, driven by strong Life Sciences growth and resilient Minerals margins. Integration of recent acquisitions is progressing, with robust cash flow and a focus on deleveraging and margin improvement.